Ground-breaking research funded by National Cancer Institute

Getty Images


September 28, 2022 —  Populations in U.S. counties defined as more vulnerable based on social factors including socioeconomic status and racial/ethnic minority status were significantly less likely to receive timely breast, cervical, and colorectal cancer screenings, according to research from UTHealth Houston

The Findings Were Published Today in JAMA Network Open

Disparities in screening rates were highly associated with a county’s social vulnerability index (SVI) – a tool that uses U.S. Census data to determine social vulnerability at a county or census tract level. The SVI is calculated using factors such as socioeconomic status, household composition, racial/ethnic minority status, housing type, transportation access, language barriers, and more among an area’s population. The index score helps public health officials and local planners better prepare for and respond to emergency events like hurricanes and disease outbreaks, which disproportionately affect areas with higher SVIs. 

The study was led by Cici Bauer, PhD, associate professor of biostatistics and data science, and Ryan Suk, PhD, assistant professor of management, policy and community health, both with UTHealth School of Public Health

“We found that counties with higher SVI scores had significantly lower screening rates for all three types of cancer,” Suk said. “These findings suggest that geographically targeted public health interventions could be further informed and improved by a composite measure reflecting the multidimensional measure of area-level social determinants of health.” 

Researchers discovered regional disparities in cancer screening rates at a county level across 3,141 U.S. counties, ranging from the lowest-performing county to the highest, including from 54.0% to 81.8% for breast cancer screening, from 69.9% to 89.7% for cervical cancer screening, and from 39.8% to 74.4% for colorectal cancer screening. 

“Even though cervical cancer screening rates are high overall, that doesn’t mean that is true everywhere,” Suk said. “Some populations have very low uptake, while in other areas, the cancer screening rate is higher than the national target rate. That’s why we have to focus on these differences by social determinants of health and not only overall average values.” 

The population-based, cross-sectional study used county-level information from the Centers for Disease Control and Prevention’s PLACES and SVI data sets from 2018 for the counties. Analyses were conducted from October 2021 to February 2022. 

Other Key Findings Included: 

The likelihood of having a cancer screening in the most vulnerable counties (or, the highest fifth) compared with the least vulnerable counties (the lowest fifth) was 14% lower for breast cancer, 20% lower for cervical cancer, and 28% lower for colorectal cancer. 

Some other area-level factors, such as rural/urban status and healthcare access in the county, were also associated with cancer screening rates. However, these factors did not further explain the geographic variation of the cancer screenings and did not change the association between social vulnerability and cancer screening rates. 

Generally, all three cancer screening rates were higher among counties on the east and west coasts and lower in the South. 

“Our study emphasizes the benefit of using geospatial analysis in population health for cancer research. It provides a powerful analytical tool to identify target areas for improving cancer prevention and reducing disparities,” Bauer said. “It also provides a way to understand how various social determinants of health may impact the cancer-related outcomes.” 

Overall, colorectal cancer screening rates were low throughout the U.S., Suk said, meaning public health experts should emphasize the importance of these screenings on a broad scale. 

For more information: https://www.uth.edu/ 


Related Content

News | Radiation Dose Management

April 25, 2024 — BIOTRONIK, a leading global medical technology company specializing in innovative cardiovascular and ...

Time April 25, 2024
arrow
News | Radiation Therapy

April 18, 2024 — Accuray Incorporated announced that as part of its commitment to advancing patient care the company has ...

Time April 18, 2024
arrow
News | FDA

April 18, 2024 — Lumicell, Inc., a privately held company focused on developing innovative fluorescence-guided imaging ...

Time April 18, 2024
arrow
News | Lung Imaging

April 17, 2024 — A Medicare policy requiring primary care providers (PCPs) to share in the decision-making with patients ...

Time April 17, 2024
arrow
News | Mammography

April 16, 2024 — The Radiological Society of North America (RSNA) and GE HealthCare announced their collaboration to ...

Time April 16, 2024
arrow
News | Clinical Trials

April 16, 2024 — QT Imaging Holdings, Inc., a medical device company engaged in research, development, and ...

Time April 16, 2024
arrow
News | Mammography

April 12, 2024 — Bayer and Hologic, Inc. announced a first-of-its-kind collaboration to deliver a coordinated solution ...

Time April 12, 2024
arrow
News | Mammography

April 12, 2024 — GE HealthCare, a leader in breast health technology and diagnostics, will feature its latest breast ...

Time April 12, 2024
arrow
News | Radiation Therapy

April 12, 2024 — RTsafe, a leading provider of quality assurance products and services in stereotactic radiosurgery, and ...

Time April 12, 2024
arrow
News | Radiation Dose Management

April 11, 2024 — Prelude Corporation (PreludeDx), a leader in precision diagnostics for early-stage breast cancer ...

Time April 11, 2024
arrow
Subscribe Now